PD-1 antibody
Quick Overview for PD-1 antibody (ABIN6940269)
Target
See all PD-1 (PDCD1) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Purified by Protein A/G
-
Immunogen
- Recombinant full-length human PDCD1 protein
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
Positive Control: TY cells. Tonsil.
Known Application: Flow Cytometry (0.5-1 μg/million cells), Immunofluorescence (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (0.5-1 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0 for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 200 μg/mL
-
Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
Expiry Date
- 24 months
-
-
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
-
Alternative Name
- PDCD1
-
Background
- PDCD-1 (programmed cell death-1 protein), also designated CD279, is a type I transmembrane receptor and a member of the immunoglobin gene superfamily. It is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PDCD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PDCD-1 is expressed by few B-cells, so anti-PDCD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PDCD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells.
-
Molecular Weight
- 55kDa
-
Gene ID
- 5133
-
UniProt
- Q15116
-
Pathways
- Cancer Immune Checkpoints
Target
-